August 13th, 2009
Pharmaceutical company NuPathe Inc., who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical trial. Zelrix is a clinically developed transdermal patch used for the treatment of acute migraines. The double-blind, placebo-controlled trial occurred in a multi-center, nonspecific, parallel group. The effectiveness and bearability of the migraine treatment was contrasted against placebo treatments in 530 adults.
Jane Hollingsworth, chief executive officer of NuPathe explains “Zelrix was designed to overcome key barriers to successful treatment of migraine; treatment-altering nausea, treatment-limiting side effects and inconsistent drug absorption.” Zelrix’s migraine patch utilizes the company’s exclusive iontophoretic transdermal technology, SmartRelief with a common prescribed treatment for migraines, sumatriptan.
Two hours post application, patients who administered the Zelrix patch showed notable advancements on all five of the key effectiveness end points, compared with those patients who administered the placebo patch. The endpoints include: pain free (pain symptom score = 0), pain relief, nausea free, photophobia free and phonophobia free.
Zelrix caused low triptan-specific side effects. The most common side effects were mild and transient itching, pain and tingling at the application site.
